Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07372040

Add-on Diuretics in Acute Decompensated Heart Failure

Led by Tanta University · Updated on 2026-02-04

66

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.

CONDITIONS

Official Title

Add-on Diuretics in Acute Decompensated Heart Failure

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female patients older than 18 years
  • Hospital admission with clinical diagnosis of acute decompensated heart failure
  • At least one clinical sign of volume overload such as edema, ascites confirmed by echography, or pleural effusion confirmed by chest X-ray or echography
Not Eligible

You will not qualify if you...

  • Type 1 diabetes
  • Chronic kidney disease with estimated glomerular filtration rate (eGFR) less than 30 mL/min per 1.73 m² or end-stage kidney failure requiring chronic dialysis
  • Systolic blood pressure less than 90 mmHg
  • Cardiogenic shock
  • Receiving acetazolamide maintenance therapy
  • Use of SGLT2 inhibitor, thiazide, or thiazide-like diuretic within 48 hours before randomization
  • Heart failure decompensation due to causes needing urgent management such as acute coronary syndrome, unstable arrhythmias, or acute pulmonary embolism
  • Pregnant or breastfeeding women
  • Moderate to severe anemia

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Tanta university

Tanta, Egypt

Actively Recruiting

Loading map...

Research Team

D

Dalia A Gomaa, MSc in clinical pharmacy

CONTACT

D

Dalia R El-Afify, Associate professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here